Zynerba Pharma (ZYNE) Adds Six New Directors
Tweet
Share
E-mailGet Alerts ZYNE Hot Sheet
Join SI Premium – FREE
Zynerba Pharma (NASDAQ: ZYNE) announced that it has appointed six new members of its board of directors. The appointees offer extensive scientific, regulatory commercial and financial experience and successful track records in development- and commercial-stage pharmaceutical companies. With these new appointments, Philip Wagenheim and Steve Gailar have resigned as members of the Zynerba board of directors.
The new Zynerba board appointments are as follows. Full biographies are available at zynerba.com.
| Warren D. Cooper, MB, BS, BSc, MPFM | Former CEO, Prism Pharmaceuticals; Merck, Sharp, Dohme |
| William J. Federici, MBA, CPA | Vice President and Chief Financial Officer of West Pharmaceutical Services |
| Thomas L. Harrison, LH.D | Chairman Emeritus of Diversified Agency Services, a division of Omnicom Group |
| Daniel L. Kisner, MD | Former venture partner/partner, Aberdare Ventures; President and CEO, Caliper Technologies |
| Kenneth I. Moch | President, Euclidean Life Science Advisors; Former President and CEO, Chimerix, BioMedical Enterprises, Alteon, and Biocyte Corporation |
| Cynthia Rask, MD | Board certified in Clinical Neurophysiology; Former Acting Director, Office of Cellular, Tissue and Gene Therapies US Food and Drug Administration (FDA); Abbott Laboratories, Genentech |
"These high-caliber board appointments well-position Zynerba, the first and only transdermal cannabinoid company, for its continued development," said Armando Anido, Chief Executive Officer (CEO) and Chairman of Zynerba Pharmaceuticals. "With such a broad range of expertise, we are confident that the board will strategically guide the company as we rapidly approach clinical development in the coming months and ultimately pursue regulatory approval and commercialization of our novel transdermal cannabinoid treatments for patients in need. We thank Phil and Steve for their support and guidance and for successfully positioning Zynerba for its introduction to the public market."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ViCentra names new CFO and adds board member ahead of U.S. expansion
- Brown-Forman CEO Lawson Whiting Planning to Step Down - WSJ
- Klaviyo names former CyberArk CFO as its next finance chief
Create E-mail Alert Related Categories
IPOs, Management Changes, Management CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
